- Home
- MPB vs ORIC Comparison
MPB vs ORIC Comparison
Compare MPB & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPB
- ORIC
- Stock Information
- Founded
- MPB 1868
- ORIC 2014
- Country
- MPB United States
- ORIC United States
- Employees
- MPB N/A
- ORIC N/A
- Industry
- MPB Major Banks
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- MPB Finance
- ORIC Health Care
- Exchange
- MPB Nasdaq
- ORIC Nasdaq
- Market Cap
- MPB 525.0M
- ORIC 633.7M
- IPO Year
- MPB N/A
- ORIC 2020
- Fundamental
- Price
- MPB $29.78
- ORIC $10.00
- Analyst Decision
- MPB Buy
- ORIC Strong Buy
- Analyst Count
- MPB 2
- ORIC 9
- Target Price
- MPB $36.00
- ORIC $18.75
- AVG Volume (30 Days)
- MPB 67.9K
- ORIC 585.0K
- Earning Date
- MPB 01-28-2025
- ORIC 03-10-2025
- Dividend Yield
- MPB 2.68%
- ORIC N/A
- EPS Growth
- MPB 14.41
- ORIC N/A
- EPS
- MPB 2.91
- ORIC N/A
- Revenue
- MPB $173,416,000.00
- ORIC N/A
- Revenue This Year
- MPB N/A
- ORIC N/A
- Revenue Next Year
- MPB $19.26
- ORIC N/A
- P/E Ratio
- MPB $10.26
- ORIC N/A
- Revenue Growth
- MPB 4.93
- ORIC N/A
- 52 Week Low
- MPB $19.20
- ORIC $6.33
- 52 Week High
- MPB $33.87
- ORIC $16.65
- Technical
- Relative Strength Index (RSI)
- MPB 55.01
- ORIC 57.64
- Support Level
- MPB $28.48
- ORIC $7.86
- Resistance Level
- MPB $29.25
- ORIC $11.15
- Average True Range (ATR)
- MPB 0.70
- ORIC 0.75
- MACD
- MPB 0.23
- ORIC 0.22
- Stochastic Oscillator
- MPB 93.36
- ORIC 65.05
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.